Akari Therapeutics PLC 2025年季度报告

(Exact name of registrant as specified in its charter) Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Y☒N☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. TABLE OF CONTENTS PART IFINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Condensed Consolidated Balance Sheets Condensed Consolidated Statements of Shareholders' Equity (Deficit)Condensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSIGNATURES GENERAL INFORMATION Unless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q ( “Form 10-Q”) to“Akari,” the “company,” the “Company,” “we,” “us,” “our” or similar designations refer to Akari Therapeutics, Plc and itssubsidiaries, taken together. All trademarks, service marks, trade names and registered marks used in this report are trademarks, Statements made in this Form 10-Q concerning the contents of any agreement, contract or other document are summaries of suchagreements, contracts or documents and are not complete description of all of their terms. If we filed any of these agreements,contracts or documents as exhibits to this Form 10-Q or to any previous filing with the Securities and Exchange Commission NOTE REGARDING FORWARD-LOOKING STATEMENTS This Form 10-Q and the documents we incorporate by reference contain forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, asamended (the “Exchange Act”). All statements, other than statements of historical fact, included or incorporated in this reportregarding, among other things, our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, relating to our competitors and our industry, the timing or likelihood of regulatory actions, filings and approvals for our current andfuture drug candidates, and the plans and objectives of management are forward-looking statements. The words “believes,”“anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “intend,”“continue,” “will,” “schedule,” “would,” “aim,” “contemplate,” “estimate,” and similar expressions are intended to identifyforward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee thatwe will actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place There are a number of important factors that could cause our actual results to differ materially from those indicated or implied byforward-looking statements. These important factors include those set forth under Part I, “Item 1A. Risk Factors” in our AnnualReport on Form 10-K for the year ended December 31, 2024 (our “Form 10-K”) and Part II “Item 1A. Risk Factors” of this Form10-Q and in our other disclosures and filings we have made with the SEC. These factors and the other cautionary statements madein this Form 10-Q and the documents we incorporate by reference should be read as being applicable to all related forward-looking In addition, any forward-looking statements represent our estimates only as of the date that this Form 10-Q is filed with the SECand should not be relied upon as representing our estimates as of any subsequent date. All forward-looking statements included inthis Form 10-Q are made as of the date hereof and are expressly qualified in their entirety by this cautionary notice. We disclaim PART I—FINANCIAL INFORMATION AKARI THERAPEUTICS, PLCCondensed Consolidated Balance She